GlaxoSmithKline plc (NYSE: GSK)

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas.
Take a look at the 1-year chart of Glaxo (NYSE: GSK) below with my added notations:

GSK has been trending lower for the past 4 months. Over that time, the stock has formed an important trend line of resistance (red). Any (2) points can start a trend line, but it’s the 3rd test and beyond that confirm its importance. GSK obviously has an important trendline of resistance, which currently sits right around $43. The stock appears to be on its way down to its $40 support (green).

The Tale of the Tape: GSK is currently stuck under a down trending resistance. A break above that resistance should mean higher prices, thus a long trade could be made either then, or on a fall to the $40 support. Short traders might look to enter a trade at the resistance.
Please share this article